Supplementary data for article: Kop, T. J.; Dordevic, J.; Bjelakovic, M. S.; Milić, D. Fullerene Bisadduct Regioisomers Containing an Asymmetric Diamide Tether. Tetrahedron 2017, 73 (50), 7073–7078. https://doi.org/10.1016/j.tet.2017.10.069 by Kop, Tatjana et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary data for article: 
 
         Kop, T. J.; Dordevic, J.; Bjelakovic, M. S.; Milić, D. Fullerene Bisadduct Regioisomers 
Containing an Asymmetric Diamide Tether. Tetrahedron 2017, 73 (50), 7073–7078. 
https://doi.org/10.1016/j.tet.2017.10.069 
 
 
 1
 
 
 
 
Supplementary Information 
 
 
 
 
Fullerene bisadduct regioisomers containing an asymmetric diamide tether 
 
Tatjana Kopa, Jelena Đorđevićb, Mira Bjelakovića, and Dragana Milićb 
 
 
a University of Belgrade - Institute of Chemistry, Technology and Metallurgy, Center for Chemistry, Njegoševa 12, 11000 Belgrade, Serbia. 
b University of Belgrade - Faculty of Chemistry, Studentski trg 12-16, 11158 Belgrade, Serbia. 
 
 
 
 
 
 
 
Content 
 
1. Experimental Section: Synthesis of compounds 2-14.         2 
2. Table S1. NMR chemical shifts (δ (ppm)) of bisadducts 17.        8 
3. Spectra of compounds 2-16.           9 
4. Spectra (IR, NMR, MS and UV) of e-edge regioisomer 17a.                 41 
5. Spectra (IR, NMR, MS and UV)  of e-face regioisomer 17b.                 46 
6. Spectra (IR, NMR, MS and UV) of trans-4 regioisomer 17c.                 51 
7. Spectra (IR, NMR, MS and UV)  of cis-2 regioisomer 17d.                 56 
 
 
 2
 
Experimental section 
General: Flash column chromatography (FCC) and dry-column flash chromatography (DCFC) were carried out with 
Merck silica gel 0.04–0.063 mm and 0.015-0.04 mm, respectively. Thin layer chromatography (TLC) was carried out 
on precoated silica gel 60 F254 plates. Melting points were determined on a Digital melting point WRS-1B apparatus 
and are uncorrected. IR spectra were recorded with a Perkin-Elmer FTIR 1725X spectrophotometer. UV spectra were 
recorded with a GBC-Cintra 40 UV-vis spectrophotometer. 1H- and 13C NMR spectra were recorded with Varian 
Gemini 200 (1H at 200 MHz, 13C at 50 MHz) and Bruker Avance spectrometers (1H at 500 MHz, 13C at 125 MHz). 
Chemical shifts are measured in ppm, J in Hz. The sample was dissolved in the indicated solvent system, and TMS 
was used as an internal reference. The homonuclear 2D (DQF-COSY) and the heteronuclear 2D 1H-13C spectra 
(HSQC, HMBC) were recorded with the usual settings. The NMR spectra of all carbamates (4−7, 11 and 12) are 
consistent with the expected structure but are complicated (splitting of some signals) by the presence of carbamate 
rotamers. The high-resolution mass spectra were obtained with an Agilent Technologies 6210 TOF LC-MS 
spectrometer. SEM: Investigations of sample morphology were carried out with SEM, using a JEOL JSM-840A 
instrument, at an acceleration voltage of 30 kV. A drop of 1 mM solution of sample in CHCl3 and ODCB was 
deposited on the surface of glass substrate and left for 24 h to slowly evaporate in a glass petri dish (diameter 10 cm) 
under a PhMe atmosphere at room temperature. The investigated samples were gold sputtered in a JFC 1100 ion 
sputterer and then subjected to SEM observations. The solvents used for the SEM experiments (HPLC grade) were 
stored over 3 Å molecular sieves and degassed under vacuum prior use.  
 
Synthesis of compounds 2-14. 
 
Compound 2. A suspension of γ-aminobutanoic acid (GABA) 1 (3.50 g, 0.034 mol), benzyl alcohol (7.30 g, 7 mL, 
0.068 mmol) and p-toluenesulfonic acid monohydrate (PTSA) (7.10 g, 0.037 mol) in PhMe (200 mL) was heated to 
reflux for 5 h with azeotropic removal of water. The reaction mixture was concentrated to a one third of the volume 
and the product precipitated by addition of Et2O (100 mL). The precipitate was filtered, dissolved in CH3OH (60 mL) 
and again precipitated by addition of Et2O (100 ml), giving after filtration and drying the benzyl ester 2 (12.30 g, 
99%) as white crystals. M.p. 106.2-106.7 ºC (Et2O); IR(ATR): 3100, 3039, 2942, 1732, 1642, 1532, 1188, 1125 cm-1; 
1H NMR (200 MHz, CD3OD): δ=7.71 (d, J=8.0 Hz, 2H, HPTSA), 7.37-7.30 (m, 5H, HCAr), 7.20 (d, J=8.4 Hz, 2H, 
HPTSA), 5.11 (s, 2H, H2CBn), 2.95 (t, J=7.5 Hz, 2H, H2C(4)GABA), 2.47 (t, J=7.3 Hz, 2H, H2C(2)GABA), 2.33 (s, 3H, 
H3CPTSA), 1.92 (quint, J=7.4 Hz, 2H, H2C(3)GABA) ppm; 13C NMR (50 MHz, CD3OD): δ=173.83 (CO2Bn), 143.35, 
141.82, 137.43, 129.91, 129.59, 129.30, 126.91 (CAr), 67.44 (CH2Bn), 40.00 (CH2(4)GABA), 31.59 (CH2(2)GABA), 23.65 
(CH2(3)GABA), 21.30 (CH3PTSA) ppm; MS(ESI): Calcd for C11H16NO2 (M+H)+: 194.1181, found: 194.1167. 
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Compound 3. A solution of the PTSA salt 2 (0.567 g, 1.6 mmol) in CH2Cl2 (15 mL) was washed with a saturated 
aqueous NaHCO3 solution (3  15 mL) and dried over anh. Na2SO4. The solvent was evaporated leaving the 
corresponding free amine, which was used in the next step. To a stirred, ice bath cooled solution of the free amine of 
2 (0.253 g, 1.3 mmol) and Et3N (263 mg, 0.5 mL)) in dry CH2Cl2 (10 mL) a solution of tert-butyl bromoacetate 
(TBBA) (255 mg, 0.21 mL, 1.3 mmol) in dry CH2Cl2 (5 mL) was added dropwise for 1 h. The reaction mixture was 
stirred with cooling for an additional 4 h. The solvent was evaporated and the remaining crude product was 
chromatographed on a SiO2 column by DCFC. Elution with PhMe/EtOAc (1/1) mixture gave the product 3 (143 mg, 
30%) as yellow oil. IR(ATR): 3340, 2979, 2938, 1743, 1695, 1238, 1167 cm-1; 1H NMR (200 MHz, CDCl3): δ=7.32-
7.15 (m, 5H, HCAr), 5.11 (s, 2H, H2CBn), 3.26 (s, 2H, H2C-CO2tBu), 2.62 (t, J=7 Hz, 2H, H2C(4)GABA), 2.43 (t, J=7.3 
Hz, 2H, H2C(2)GABA), 1.82 (quint, J=7.0 Hz, 2H, H3C(3)GABA), 1.46 (s, 9H, H3CtBu) ppm; 13C NMR (50 MHz, 
CDCl3): δ=173.30 (CO2Bn), 171.71 (CO2tBu), 135.99, 128.98, 127.47, 126.89 (CAr), 81.10 (CtBu), 66.09 (CH2Bn), 
51.47 (CH2CO2tBu), 48.52 (CH2(4)GABA), 31.90 (CH2(2)GABA), 28.00 (CH3tBu), 25.15 (CH2(3)GABA) ppm; MS(ESI): 
Calcd for C17H26NO4  (M+H)+: 308,1856, found: 308,1861. 
 
Compound 4. To a stirred, ice bath cooled solution of compound 3 (0.73 g, 2.4 mmol) in CHCl3 (15 mL) a solution 
of di(tert-butyl)dicarbonate (Boc2O, 1.05 g, 4.8 mmol) in CHCl3 (10 mL) was added dropwise. After additional 
stirring for 24 h, the mixture was washed with brine and dried over anh. Na2SO4. The solvent was removed in vacuo 
and the remaining material was purified on a SiO2 column by DCFC. Elution with PhMe/EtOAc (8/2) gave N-Boc 
protected compound 4 as yellow oil (0.76 g, 78%). IR(ATR): 2977, 2934, 1742, 1701, 1458, 1367, 1247, 1153 cm-1; 
1H NMR (500 MHz, CDCl3, compound exists as a 40:60 mixture of rotamers): δ=7.35 (s, 5H, HCAr), 5.12 (s, 2H, 
H2CBn), 3.81 and 3.72 (two s, 2H, H2C-CO2tBu), 3.32 and 3.28 (two t, J=6.8 Hz, 2H, H2C(4)GABA), 2.41 and 2.40 
(two t, J=7.6 Hz, 2H, H2C(2)GABA), 1.86 (quint, J=7.3 Hz, 2H, H2C(3)GABA), 1.45 and 1.43 (two s, 18H, H3CtBu) ppm; 
13C NMR (125 MHz, CDCl3): δ=173.13, 172.97 (CO2Bn), 169.17 (CO2tBu), 155.64, 155.39 (COBoc), 135.98, 128.53, 
128.19 (CAr), 81.37, 80.08 and 79.94 (CtBu), 66.17 (CH2Bn), 50.29 and 49.67 (CH2-CO2tBu), 47.65 (CH2(4)GABA), 
31.32 (CH2(2)GABA), 28.15, 28.04 and 27.94 (CH3tBu), 23.68, 23.46 (CH2(3)GABA) ppm; MS(ESI): Calcd for 
C22H33NNaO6  (M+Na)+: 430.2200, found 430.2183. 
 
Compound 5. To a solution of benzyl ester 4 (1.23 g, 3.0 mmol) in MeOH (100 mL) 5% Pd/C (123 mg) was added 
and suspension was bubbled with argon. Mixture was hydrogenated at 40 psi at room temperature for 1 h. After 
filtering the catalyst and evaporating the solvent, crude acid 5 was isolated as colorless oil (0.95 g; 99%). IR(ATR): 
 4
3188, 2979, 2936, 1744, 1707, 1476, 1370, 1251, 1158 cm-1; 1H NMR (500 MHz, CD3OD): δ=3.83 and 3.82 (two s, 
2H, H2C-CO2tBu), 3.34-3.29 (m, 2H, H2C(4)GABA), 2.34 and 2.33 (two t, J=7.5 Hz, 2H, H2C(2)GABA), 1.80 (m, 2H, 
H2C(3)GABA), 1.48, 1.47, 1.46, 1.43 (4s, 18H, H3CtBu) ppm; 13C NMR (125 MHz, CD3OD): δ=177.19, 177.03 
(COOH), 171.11, 170.99 (CO2tBu), 157.73, 157.49 (COBoc), 82.88, 82.79, 81.81, 81.60 (CtBu), 51.40, 50.98, 50.00 
(CH2-CO2tBu, CH2(4)GABA), 32.20, 31.96 (CH2(2)GABA), 28.77, 28.71, 28.50, 28.46 (CH3tBu), 24.87, 24.76 
(CH2(3)GABA) ppm; MS(ESI): Calcd for C15H27NNaO6 (M+Na)+: 340,1731, found: 340,1714; Calcd for C15H27KNO6  
(M+K)+ : 356,1470, found: 356,1456. 
 
Compound 6. To a solution of acid 5 (55 mg, 0.17 mmol, 1 equiv.), DCC (70.2 mg, 0.34 mmol, 2 equiv.), and 
DMAP (2.1 mg, 0.017 mmol, 0.1 equiv.) and Et3N (17.2 mg, 0.02 mL) in dry CH2Cl2 (2 mL), a solution of glycine 
benzyl ester (GlyOBn, 28.1 mg, 0.17 mmol, 1 equiv.) in CH2Cl2 (1 mL) was added dropwise under an atmosphere of 
argon. The reaction mixture was stirred for 48 h. The solvent was evaporated to dryness and the reaction mixture was 
purified by FCC on SiO2. Elution with PhMe/EtOAc 7:3 gave the amide 6 (40 mg, 50%) as colorless oil. IR(ATR): 
3332, 2977, 2936, 1747, 1697, 1459, 1368, 1249, 1176 cm-1; 1H NMR (200 MHz, CDCl3, compound exists as a 
75:25 mixture of rotamers): δ=7.43-7.05 (m, 5H, HCAr), 7.03 and 6.22 (2 br s, NH), 5.17 (s, 2H, H2CBn), 4.07 (d, 
J=5,8 Hz, 2H, H2C-CO2Bn), 3.82 and 3.73 (two s, 2H, H2C-CO2tBu), 3.34 (t, J=6,2 Hz, 2H, H2C(4)GABA), 2.30 (t, 
J=7,0 Hz, 2H, H2C(2)GABA), 1.90-1.72 (m, 2H, H2C(3)GABA), 1.46 and 1.44 (two s, 18H, CH3tBu) ppm; 13C NMR (50 
MHz, CDCl3): δ=173.43 (COGABA), 169.88 and 169.22 (CO2Bn, CO2tBu), 156.11 (COBoc), 135.34, 129.00, 128.58, 
128.34, 125.27 (CAr), 81.48, 80.26 (CtBu), 66.97 (CH2Bn), 50.34 (CH2-CO2tBu), 47.34 (CH2(4)GABA), 41.37 (CH2-
CO2Bn), 33.14 (CH2(2)GABA), 28.21 and 27.99 (CH3tBu), 24.60 (CH2(3)GABA) ppm; MS(ESI): Calcd for C24H37N2O7 
(M+H)+: 465.2595, found 465.2575. 
 
Compound 7. To a solution of benzyl ester 6 (340 mg, 0.73 mmol) in MeOH (100 mL) 5% Pd/C (34 mg) was added 
and suspension was bubbled with argon. Mixture was hydrogenated (40 psi) at room temperature for 1 h. After 
filtering the catalyst and evaporating the solvent, crude acid 7 (272 mg, 99 %) was isolated as colorless oil. IR(ATR): 
3395, 2979, 2935, 2488, 1740, 1681, 1475, 1370, 1251, 1159 cm-1; 1H NMR (200 MHz, CD3OD, compound exists as 
a 48:52 mixture of rotamers): δ=3.89 and 3.84 (two s, 4H, H2C-CO2tBu, H2C-CO2H), 3.30 (m, 2H, H2C(4)GABA), 2.28 
(t, J=7,3 Hz, 2H, H2C(2)GABA), 1.83 (m, 2H, H2C(3)GABA), 1.47 and 1.43 (two s, 18H, CH3tBu) ppm; 13C NMR (50 
MHz, CD3OD): δ=176.05, 175.91 (CO2H), 173.16 (COGABA), 171.10 (CO2tBu), 157.63, 157.46 (COBoc), 82.72 and 
81.54 (CtBu), 51.29, 51.02, 50.28 and 47.72 (CH2-CO2tBu, CH2(4)GABA ), 41.83 (CH2-CO2H), 34.73 and 33.82 
(CH2(2)GABA), 28.57and 28.33 (CH3tBu), 26.71, 26.02, 25.62, 25.35 (CH2(3)GABA) ppm; MS(ESI): Calcd for 
C17H31N2O7 (M+H)+: 375.2126, found 375.2129. 
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Compound 9. Solution of Boc2O (0.5 M; 1.83 g; 8.6 mmol) in CHCl3 (17 mL) was added dropwise to a stirred ice-
cooled 0.25 M solution of 1,6-hexanediamine 8 (5.00 g; 43.0 mmol) in CHCl3 (172 mL), for 6 h. Stirring was 
continued at room temperature for the next 18 h. Suspension was filtered over a sintered funnel and the solvent was 
evaporated under vacuum. The residual mixture was redissolved in EtOAc (50 mL), washed with a saturated aqueous 
NaCl solution (4×15 mL), and dried over anh. Na2SO4. Solvent was removed under vacuum, yielding 9 as colorless 
oil (1.48 g, 80%). Further purification was not necessary. (If it is necessary, product may be purified by DCFC on 
silica-gel, with solvent mixtures EtOAc/MeOH/NH3 (80:20:3→80:20:10) as eluents). IR(ATR): 3363, 2931, 1700, 
1176, 871 cm-1; 1H NMR (200 MHz, CDCl3): δ=4.97 (s, 1H, NH-Boc), 3.10 (q, J=6.2 Hz, 2H, H2C-NHBoc), 2.68 (t, 
J=6.2 Hz, 2H, H2C-NH2), 1.44 (s, 9H, H3CBoc), 1.52 (s, 2H, NH2), 1.51-1.25 (m, 8H, H2C2-5) ppm; 13C NMR (50 
MHz, CDCl3): δ=155.9 (COBoc), 78.5 (CBoc), 41.8 (CH2-NH2), 40.2 (CH2-NHBoc), 33.3, 29.8 (2CH2), 28.1 (CH3Boc), 
26.3, 26.2 (2CH2) ppm; ESI-TOF-MS: m/z: Calculated for C11H25N2O2: 217.1910 [M+H]+; found 217.1912. 
 
Compound 10. Solution of BBA (0.844 g; 0.582 mL; 3.70 mmol; 1 equiv.) in dry CH2Cl2 (6.75 mL) was added 
dropwise into a stirred solution of amine 9 (1.00 g, 4.63 mmol; 1.25 equiv.) and Et3N (0.374 g; 0.515 mL; 3.70 mmol; 
1 equiv.) in dry CH2Cl2 (19.2 mL), at 0 °C. The addition of BBA solution was completed after 1 h. The reaction 
mixture was then stirred at room temperature for 24 h, washed with H2O (3×15 mL) and saturated aqueous NaCl 
(2×15 mL), and dried over anh. NaSO4. After filtering and evaporation of the solvent, the reaction mixture was 
purified by DCFC on SiO2. Elution with EtOAc gave compound 10 as pale yellow oil (0.813 g; 60%). IR(ATR): 
3346, 2974, 2932, 2858, 1741, 1711, 1524, 1457, 1366, 1251, 1175, 967, 751, 700 cm-1; 1H NMR (200 MHz, 
CDCl3): δ = 7.36 (s, 5H, HCAr), 5.17 (s, 2H, H2CBn), 4.55 (s, 1H, NH-Boc), 3.45 (s, 2H, H2C-CO2Bn), 3.10 (q, J=6.2 
Hz, 2H, H2C-NHBoc), 2.59 (t, J=6.7 Hz, 2H, H2C-NH-GlyOBn), 1.70 (s, 1H, NH-GlyOBn), 1.44 (s, 9H, H3CBoc), 
1.57-1.26 (m, 8H, H2C2-5) ppm; 13C NMR (50 MHz, CDCl3): δ = 172.5 (CO2Bn), 156.0 (COBoc), 135.6 (CAr), 128.6; 
128.4 (CHAr), 79.0 (CBoc), 66.5 (CH2Bn), 50.9 (CH2-CO2Bn), 49.4 (CH2-NHGlyOBn), 40.5 (CH2-NHBoc), 29.9 
(2CH2), 28.4 (CH3Boc), 26.8, 26.6 (2CH2) ppm; ESI-TOF-MS: m/z: calculated for C20H33N2O4: 365.2435 [M+H]+, 
found 365.2428. 
 
Compound 11. Solution of benzyl chloroformate (ZCl, 439 mg, 433 µL, 2.56 mmol, 1.1 equiv.) in dry CH2Cl2 (39 
mL) was added dropwise in solution of compound 10 (850 mg; 2.33 mmol; 1 equiv.) and Et3N (704 mg, 970 µL, 6.99 
mmol, 3 equiv.) in dry CH2Cl2 (116 mL), at 0 °C for 2 h. Reaction mixture was stirred for additional 2 h at room 
temperature, and purified by DCFC on SiO2. Elution with mixtures of solvents PhMe/EtOAc (9:1→1:1) afforded 
pure product 11 as yellow oil (0.99 g, 83%). IR(ATR): 3373, 2975, 2936, 2836, 1745, 1712, 1520, 1457, 1390, 1366, 
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1252, 1176, 999, 743, 700 cm-1; 1H NMR (200 MHz, CDCl3, compound exists as a mixture of rotamers): δ=7.38-7.13 
(m, 10H, HCAr), 5.18, 5.16 (2s, 2H, H2CBn), 5.09, 5.08 (2s, 2H, H2CZ), 4.58 (br s, 1H, NHBoc), 4.06, 3.98 (2s, 2H, 
H2C-CO2Bn), 3.32 (q, J=7.0 Hz, 2H, H2C-N(Z)GlyOBn), 3.08 (q, J=6.0 Hz, 2H, H2C-NHBoc), 1.44 (s, 9H, CH3Boc), 
1.27, 1.22 (2br s, 8H, H2C2-5) ppm; 13C NMR (50 MHz, CDCl3): δ=169.6 (CO2Bn), 156.5 (COZ), 155.9 (COBoc); 
155.7 (COZ), 136.5 (CAr(Z)), 135.3 (CAr(Bn)), 128.5, 128.34, 128.29, 128.1, 127.85, 127.82, 127.6 (CHAr), 78.8 (CBoc), 
67.3, 67.1 (CH2Z), 66.73, 66.68 (CH2Bn), 49.0, 48.8, 48.1 (CH2-CO2Bn, CH2-N(Z)GlyOBn), 40.4 (CH2-NHBoc), 
29.8, 29.0 (2CH2), 28.4 (CH3Boc), 28.1, 27.7, 26.5, 26.4 (2CH2) ppm. ESI-TOF-MS: m/z: calculated for 
C28H38N2O6Na: 521.2622 [M+Na]+; found 521.2620. 
 
Compound 12. To the solution of compound 11 (500 mg; 1.00 mmol) in CH2Cl2 (1 mL) TFA (1 mL) was added, and 
reaction mixture was stirred overnight at room temperature. Solvent and TFA were removed from the mixture by 
successive co-evaporations with PhMe (5×5 mL, at least). TFA salt 12 remained as colorless oil (510 mg, 100%). 
IR(ATR): 3067, 2942, 2872, 1694, 1622, 1596, 1533, 1496, 1436, 1190, 1140, 948, 838, 799, 723 cm-1; 1H NMR 
(200 MHz, CDCl3, compound exists as a mixture of rotamers): δ=7.63 (br s, 3H, NH3+), 7.40-7.15 (m, 8H, HCAr), 
6.93 (br s, 2H, HCAr), 5.14, 5.13, 5.08, 5.03 (4s, 4H, H2CBn,Z), 4.01, 3.96, 3.91 (3s, 2H, H2C-CO2Bn), 3.30 (br s, 2H, 
H2C-N(Z)GlyOBn), 2.84 (br s, 2H, H2C-NHBoc), 1.68-1.40 (m, 4H), 1.40-1.12 (m, 4H) ppm; 13C NMR (50 MHz, 
CDCl3): δ=169.6 (CO2Bn), 161.6 (q, 2JC,F =40 Hz, COTFA), 157.2, 157.7, 156.4 (COZ), 136.2 (CZ), 135.2 (CBn), 128.6, 
128.5, 128.3, 128.1, 127.8, 127.5, 127.1 (CAr), 116.0 (q, 1JC,F=290 Hz, CF3), 67.6 (CH2Z), 67.0 (CH2Bn), 49.2, 48.9 
(CH2-CO2Bn), 48.3, 48.2 (CH2N(Z)GlyOBn), 39.7, 39.6 (CH2-NH3+), 27.9, 27.3, 26.9, 25.8, 25.1 (CH22-5) ppm; ESI-
TOF-MS: m/z: calculated for C23H31N2O4: 399.2278 [M - CF3COO-]+; found 399.2266. 
 
Compound 13. To an ice bath cooled solution of TFA salt 12 (77.3 mg, 0.15 mmol, 1 equiv.), Et3N (30.3 mg, 0.05 
mL, 0.3 mmol, 1 equiv.) in CH2Cl2 (1 mL), acid 7 (56.3 mg, 0.15 mmol, 1 equiv.) and DMAP (1.8 mg, 0.015 mmol) 
were added. A solution of DCC (61.9 mg, 0.3 mmol, 2 equiv.) in DCM (1 mL) was added to the reaction mixture (2 
h) and stirred for 24 h. The solvent was evaporated in vacuo and the residue chromatographed by DCFC on SiO2 
column using EtOAc/MeOH 50:1 to obtain amide 13 (65 mg, 57%) as yellow oil. IR(ATR): 3350, 2976, 2935, 2861, 
1747, 1698, 1542, 1460, 1248, 1172 cm-1; 1H NMR (200 MHz, CDCl3, compound exists as a mixture of rotamers): 
δ=7.40-7.20 (m, 10H, HCAr), 6.88 (m, 1H, HN), 6.64 (m, 1H, HN), 5.18, 5.16, 5.10, 5.08 (4s, 4H, H2CBn, H2CZ), 
4.10-3.70 (m, 6H, H2CGly), 3.31 (m, 4H, H2C(1, 6hexyl)), 3.20 (t, J=6.2 Hz, 2H, H2C(4)GABA), 2.32 (t, J=7.0, 2H, 
H2C(2)GABA), 1.82 (m, 2H, H2C(3)GABA), 1.47 and 1.43 (two s, 18H, CH3tBu) ppm; 13C NMR (50 MHz, CDCl3): 
δ=173.36 (COGABA), 169.27, 169.14 (COGly), 156.56, 156.19, 155.93 (NCO2Bn, NCO2tBu), 136.56, 136.48, 135.35, 
128.59, 128.43, 128.27, 127.95 (CAr), 81.58 and 80.36 (CtBu), 67.40, 67.29 and 66.87 (CH2Bn), 50.24, 49.12, 48.89, 
48.59, 48.18, 47.13 (CH2GlyOBn, CH2GlyOtBu, CH2(4)GABA, CH2N(Z)GlyOBn), 43.51 (CH2Gly), 39.29, 39.12 (CH2), 
 7
32.78 (CH2(2)GABA), 29.33, 29.22 (CH2), 28.18, 28.02 (CH3tBu), 27.70, 26.47, 26.25, 25.98 (CH2), 24.22 
(CH2(3)GABA) ppm; MS(ESI): Calcd for C40H59N4O10 (M+H)+: 755.4226, found 755.4220. 
 
 
12. Compound 14. To a solution of benzyl ester 13 (165 mg, 0.22 mmol) in MeOH (100 mL) 5% Pd/C (16.5 mg) 
was added and suspension was bubbled with argon. Mixture was hydrogenated at 40 psi for 24 h. After filtering the 
catalyst and evaporating the solvent, crude acid 14 (115.1 mg, 99%) was isolated as colorless oil. 
IR(ATR): 3378, 3054, 2979, 2936, 2862, 2497, 1743, 1650, 1462, 1369, 1266, 1156 cm-1; 1H NMR (500 MHz, 
CD3OD, compound exists as a mixture of rotamers): δ=3.88/3.85 (minor) and 3.83/3.80 (major) (four s, 4H, 
H2CGlyOtBu, H2CGly(amide)), 3.48 (s, 2H, H2CGlyOH), 3.33-3.28 (m, 2H, H2C(6)hexyl), 3.23/3.20 (two t, J=7.5 Hz, 2H, 
H2C(1)hexyl)), 2.99 (br t, J=7.5 Hz, 2H, H2C(4)GABA), 2.32/2.30 (m, 2H, H2C(2)GABA), 1.81 (m, 2H, H2C(3)GABA), 
1.48/1.44 (major) and 1.47/1.46 (minor) (four s, 18H, CH3tBu) ppm; 13C NMR (50 MHz, CD3OD): δ=176.06 
(COOH), 172.02, 171.73, 171.14, 171.02, 170.94 (CO), 157.69 (COBoc), 82.86, 82.78, 81.75, 81.60 (CtBu), 51.16, 
51.03, 50.80, 48.69, 48.46 (CH2GlyOtBu, CH2GlyOH), 43.94, 43.67 (CH2Gly), 40.24, 40.19 (CH2NHGlyOH), 33.99, 33.38 
(CH2(1)hexyl), 33.38 (CH2(2)GABA), 30.25 (CH2(2)GABA), 28.81/28.48 (minor) and 28.77/28.53 (major) (CH3tBu), 27.33, 
27.25, 27.21 (CH2hexyl), 25.68, 24.95 (CH2(3)GABA) ppm; MS(ESI): Calcd for C25H47N4O8 (M+H)+: 531.3388, 
(M+Na)+: 553.3208; found: 531.3374, 553.3188. 
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Table S1. 1H /13C NMR chemical shifts (δ (ppm)) of bisadducts 17. 
 
 17a (e-edge) 
 
17b (e-face)
 
17c (trans-4)
 
17d (cis-2) 
 
HC(pyrr-1) 4.05s/65.02 
4.04s/68.46 
4.33d; 3.71d/66.92 4.60d; 3.84d/68.5
4.58d; 3.57d/66.69 
4.23d; 3.58d/66.52 
3.95d; 3.73d/67.77 
sp3C(full) 69.44; 69.90 70.22 69.80; 69.41;
69.24; 69.17 
67.14; 66.95; 
66.74; 66.68 
H2C(1) 2.92/53.95 2.91/52.21 3.04-2.98/54.00 2.98;2.75/53.81 
H2C(2) 1.76/24.47 1.69/25.95 1.91-1.72/27.06 1.88;1.71/26.85 
H2C(3) 1.76/27.08 1.69/27.56 1.91-1.74/26.24 1.76;1.52/25.21 
H2C(4) 1.46/25.11 1.42/26.22 1.61-1.50/25.47 1.47/25.39 
H2C(5) 1.59/28.11 1.55/29.62 1.61-1.50/29.35 1.65/28.15 
H2C(6) 3.21/38.27 3.20/39.85 3.33;3.22/39.23 3.42;3.06/39.36 
NH-hexyl 5.61 5.65 5.60 6.00
CO-Gly 167.74 168.59 168.19 168.72 
H2C-Gly 3.90/42.51 3.83/42.76 3.87; 3.68/43.13 4.11;3.76/43.30 
NH-Gly 6.85 7.20 6.86 6.93
CO-GABA 172.84 173.77 172.96 173.72 
H2C(2)-GABA 2.60/33.17 2.65/33.54 2.61-2.46/34.75 2.62;2.47/33.86 
H2C(3)-GABA 2.09/23.36 2.13/23.82 2.89; 2.06/22.80 2.10/24.28 
H2C(4)-GABA 2.90/51.13 3.12/50.77 3.08; 2.96/51.93 3.04;2.94/52.02 
HC(pyrr-2) 4.29d; 3.65d/67.10 4.04s/67.53; 65.37 4.60d; 3.85d/67.62
4.44d; 3.70d/67.07 
4.36d; 3.87d/67.98 
3.96d; 3.72d/65.88 
sp3C(full) 69.57 69.44; 69.73
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Compound 2 
 
 
 
Figure S1. IR spectrum of 2 
 
 
Figure S2. Mass spectum of 2 
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Figure S3. 1H NMR spectrum of 2 
 
 
 
Figure S4. 13C NMR spectrum of 2 
 11
Compound 3 
 
 
 
Figure S5. IR spectrum of 3 
 
 
Figure S6. Mass spectrum of 3 
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(a) 
 
(b) 
 
Figure S7. 1H NMR spectra of 3 immediately after isolation (a) and lactam formed upon standing (b) 
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Figure S8. 13C NMR spectrum of 3 
 
 
 
Compound 4 
 
 
 
 
Figure S9. IR spectrum of 4 
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Figure S10. Mass spectrum of 4 
 
 
Figure S11. 1H NMR spectrum of 4 
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Figure S12. 13C NMR spectrum of 4 
 
 
Compound 5 
 
 
 
 
Figure S13. IR spectrum of 5 
 16
 
 
 
Figure S14. Mass spectrum of 5 
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Figure S15. 1H NMR spectrum of 5 
 
 
 
Figure S16. 13C NMR spectrum of 5 
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Compound 6 
 
 
 
 
Figure S17. IR spectrum of 6 
 
 
Figure S18. Mass spectrum of 6 
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Figure S19. 1H NMR spectrum of 6 
 
 
Figure S20. 13C NMR spectrum of 6 
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Compound 7 
 
 
 
 
Figure S21. IR spectrum of 7 
 
 
 
Figure S22. Mass spectrum of 7 
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Figure S23. 1H NMR spectrum of 7 
 
 
 
Figure S24. 13C NMR spectrum of 7 
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Compound 9 
 
 
 
 
Figure S25. IR spectrum of 9 
 
 
 
Figure S26. Mass spectrum of 9 
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Figure S27. 1H NMR spectrum of 9 
 
 
 
Figure S28. 13C NMR spectrum of 9 
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Compound 10 
 
 
 
 
Figure S29. IR spectrum of 10 
 
 
 
Figure S30. Mass spectrum of 10 
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Figure S31. 1H NMR spectrum of 10 
 
 
Figure S32. 13C NMR spectrum of 10 
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Compound 11 
 
 
 
 
Figure S33. IR spectrum of 11 
 
 
Figure S34. Mass spectrum of 11 
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Figure S35. 1H NMR spectrum of 11 
 
 
 
Figure S36. 13C NMR spectrum of 11 
 28
Compound 12 
 
 
 
 
Figure S37. IR spectrum of 12 
 
 
 
Figure S38. Mass spectrum of 12 
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Figure S39. 1H NMR spectrum of 12 
 
 
 
Figure S40. 13C NMR spectrum of 12 
 30
Compound 13 
 
 
 
 
Figure S41. IR spectrum of 13 
 
 
Figure S42. Mass spectrum of 13 
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Figure S43. 1H NMR spectrum of 13 
 
 
 
Figure S44. 13C NMR spectrum of 13 
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Compound 14 
 
 
 
 
Figure S45. IR spectrum of 14 
 
 
Figure S46. Mass spectrum of 14 
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Figure S47. 1H NMR spectrum of 14 
 
 
Figure S48. 13C NMR spectrum of 14 
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Compound 15 
 
 
 
 
Figure S49. IR spectrum of 15 
 
 
Figure S50. 1H NMR spectrum of 15 
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Figure S51. Expanded parts of 1H NMR spectrum of 15 
 
 
 
Figure S52. 13C NMR spectrum of 15 
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Figure S53. COSY spectrum of 15 
 
 
 
Figure S54. HSQC spectrum of 15 
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Figure S55. HMBC spectrum of 15 
 
 
 
Figure S56. Mass spectrum of 15 
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Figure S57. UV spectrum of 15 
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Compound 16 
 
 
 
 
Figure S58. IR spectrum of 16 
 
 
Figure S59. UV spectrum of 16 
 40
 
Figure S60. Mass spectrum of 16 
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Spectra of bisadducts 17a-d 
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Bisadduct 17a (e-edge) 
 
 
Figure S61. IR spectrum of 17a 
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Figure S62. 1H NMR spectrum of 17a 
 
 
 
 
Figure S63. 13C NMR spectrum of 17a 
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Figure S64. COSY spectrum of 17a 
 
 
 
Figure S65. HSQC spectrum of 17a 
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Figure S66. HMBC spectrum of 17a 
 
 
Figure S67. UV spectrum of 17a  
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Figure S68. Mass spectrum of 17a
 46
Bisadduct 17b (e-face) 
 
 
Figure 69. IR spectrum of 17b 
 
 47
 
 
Figure S70. 1H NMR spectrum of 17b 
 
 
 
Figure S71. 13C NMR spectrum of 17b 
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Figure S72. COSY spectrum of 17b 
 
 
 
Figure S73. HSQC spectrum of 17b 
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Figure S74. HMBC spectrum of 17b 
 
 
Figure S75. UV spectrum of 17b 
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Figure S76. Mass spectrum of 17b 
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 Bisadduct 17c (trans-4) 
 
 
 
Figure S77. IR spectrum of 17c 
 
 
 
Figure S78. 1H NMR spectrum of 17c 
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Figure S79. Expanded parts of 1H NMR spectrum of 17c 
 
 
 
Figure S80. 13C NMR spectrum of 17c 
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Figure S81. COSY spectrum of 17c 
 
 
 
Figure S82. HSQC spectrum of 17c 
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Figure S83. HMBC spectrum of 17c 
 
 
 
Figure S84. Expanded part of HMBC spectrum of 17c 
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Figure S85. UV spectrum of 17c 
 
 
Figure S86. Mass spectrum of 17c 
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Bisadduct 17d (cis-2) 
 
 
Figure S87. IR spectrum of 17d 
 
 
 
 
Figure S88. 1H NMR spectrum of 17d 
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Figure S89. 13C NMR spectrum of 17d 
 
 
 
Figure S90. COSY spectrum of 17d 
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Figure S91. HSQC spectrum of 17d 
 
 
 
Figure S92. HMBC spectrum of 17d 
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Figure S93. UV spectrum of 17d 
 
 
Figure S94. Mass spectrum of 17d 
